{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T08:05:31Z","timestamp":1789632331401,"version":"build-2803163510"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"DOI":"10.1007\/s00280-026-04948-z","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T07:42:58Z","timestamp":1789630978000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Risk factors associated with febrile neutropenia in patients with esophageal cancer receiving 5-fluorouracil plus cisplatin combination chemoradiotherapy"],"prefix":"10.1007","volume":"96","author":[{"given":"Daiki","family":"Eto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2626-1711","authenticated-orcid":false,"given":"Ken","family":"Shiraiwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryota","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Sumimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Tatsuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"issue":"1","key":"4948_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-023-08058-6","volume":"23","author":"N Joudeh","year":"2023","unstructured":"Joudeh N, Sawafta E, Abu Taha A, Hamed Allah M, Amer R, Odeh RY, Salameh H, Sabateen A, Aiesh BM, Zyoud SH (2023) Epidemiology and source of infection in cancer patients with febrile neutropenia: an experience from a developing country. BMC Infect Dis 23(1):106. https:\/\/doi.org\/10.1186\/s12879-023-08058-6","journal-title":"BMC Infect Dis"},{"issue":"28","key":"4948_CR2","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","volume":"33","author":"TJ Smith","year":"2015","unstructured":"Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, Goldberg JM, Khatcheressian JL, Leighl NB, Perkins CL, Somlo G, Wade JL, Wozniak AJ (2015) Recommendations for the use of WBC growth factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 33(28):3199\u20133212. https:\/\/doi.org\/10.1200\/JCO.2015.62.3488","journal-title":"J Clin Oncol"},{"issue":"5","key":"4948_CR3","doi-asserted-by":"publisher","first-page":"436","DOI":"10.6004\/jnccn.2022.0026","volume":"20","author":"EA Griffiths","year":"2022","unstructured":"Griffiths EA, Roy V, Alwan L, Bachiashvili K, Baird J, Cool R, Dinner S, Geyer M, Glaspy J, Gojo I, Hicks A, Kallam A, Kidwai WZ, Kloth DD, Kraut EH, Landsburg D, Lyman GH, Mahajan A, Miller R, Nachar V, Patel S, Patel S, Perez LE, Poust A, Riaz F, Rosovsky R, Rugo HS, Simon S, Vasu S, Wadleigh M, Westbrook K, Westervelt P, Berardi RA, Pluchino L (2022) NCCN guidelines\u00ae insights: hematopoietic growth factors, version 1.2022. J Natl Compr Canc Netw 20(5):436\u2013442. https:\/\/doi.org\/10.6004\/jnccn.2022.0026","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"4948_CR4","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s12957-019-1665-x","volume":"17","author":"Y Ohkura","year":"2019","unstructured":"Ohkura Y, Ueno M, Udagawa H (2019) Risk factors for febrile neutropenia and effectiveness of primary prophylaxis with pegfilgrastim in patients with esophageal cancer treated with docetaxel, cisplatin, and 5-fluorouracil. World J Surg Oncol 17(1):125. https:\/\/doi.org\/10.1186\/s12957-019-1665-x","journal-title":"World J Surg Oncol"},{"issue":"4","key":"4948_CR5","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1007\/s00520-019-05001-x","volume":"28","author":"H Nomura","year":"2020","unstructured":"Nomura H, Hatogai K, Maki Y, Mochizuki N, Tanaka M, Saito S, Daiko H, Kojima T, Kawasaki T (2020) Risk factors for febrile neutropenia in neoadjuvant docetaxel, cisplatin, and 5-fluorouracil chemotherapy for esophageal cancer. Support Care Cancer 28(4):1849\u20131854. https:\/\/doi.org\/10.1007\/s00520-019-05001-x","journal-title":"Support Care Cancer"},{"issue":"10","key":"4948_CR6","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1093\/jjco\/hyh107","volume":"34","author":"K Ishida","year":"2004","unstructured":"Ishida K, Ando N, Yamamoto S, Ide H, Shinoda M (2004) Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)\/Japan Clinical Oncology Group trial (JCOG9516). Jpn J Clin Oncol 34(10):615\u2013619. https:\/\/doi.org\/10.1093\/jjco\/hyh107","journal-title":"Jpn J Clin Oncol"},{"key":"4948_CR7","volume-title":"Guidelines for the management of febrile neutropenia","author":"Japanese Society of Medical Oncology (JSMO)","year":"2023","unstructured":"Japanese Society of Medical Oncology (JSMO) (2023) Guidelines for the management of febrile neutropenia, 3rd edition. Nankodo, Tokyo","edition":"3rd edition"},{"key":"4948_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2023.1043550","volume":"10","author":"J Wei","year":"2023","unstructured":"Wei J, Lu J, Jia H, Yang X, Guo X, Liu J, Li X (2023) Value of a preoperative prognostic nutritional index for the prognostic evaluation of gastric neuroendocrine carcinoma patients. Front Nutr 10:1043550. https:\/\/doi.org\/10.3389\/fnut.2023.1043550","journal-title":"Front Nutr"},{"issue":"8","key":"4948_CR9","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.3919\/jjsa.76.1819","volume":"76","author":"Y Nakahara","year":"2015","unstructured":"Nakahara Y, Yamasaki M, Makino T, Miyazaki Y, Takahashi T, Kurokawa Y, Nakajima K, Takiguchi S, Mori M, Doki Y (2015) Factors associated with febrile neutropenia caused by combined chemotherapy with docetaxel, cisplatin and 5-FU for esophageal cancer. J Jpn Surg Assoc 76(8):1819\u20131824. https:\/\/doi.org\/10.3919\/jjsa.76.1819","journal-title":"J Jpn Surg Assoc"},{"issue":"13","key":"4948_CR10","doi-asserted-by":"publisher","first-page":"4754","DOI":"10.1245\/s10434-019-07744-7","volume":"26","author":"T Hagi","year":"2019","unstructured":"Hagi T, Makino T, Yamasaki M, Tanaka K, Nishida N, Sakai D, Motoori M, Kimura Y, Satoh T, Mori M, Doki Y (2019) Dysphagia score as a predictor of adverse events due to triplet chemotherapy and oncological outcomes in 434 consecutive patients with esophageal cancer. Ann Surg Oncol 26(13):4754\u20134764. https:\/\/doi.org\/10.1245\/s10434-019-07744-7","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"4948_CR11","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.21873\/anticanres.16395","volume":"43","author":"J Hashizume","year":"2023","unstructured":"Hashizume J, Nambu M, Nakagawa H, Harasawa H, Kodama Y (2023) Poor renal function and a high modified Glasgow prognostic score are predictive factors for nedaplatin\/5-fluorouracil combination therapy-induced febrile neutropenia. Anticancer Res 43(5):2309\u20132316. https:\/\/doi.org\/10.21873\/anticanres.16395","journal-title":"Anticancer Res"},{"issue":"3","key":"4948_CR12","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.critrevonc.2013.12.006","volume":"90","author":"GH Lyman","year":"2013","unstructured":"Lyman GH, Abella E, Pettengell R (2013) Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: a systematic review. Crit Rev Oncol Hematol 90(3):190\u2013199. https:\/\/doi.org\/10.1016\/j.critrevonc.2013.12.006","journal-title":"Crit Rev Oncol Hematol"},{"key":"4948_CR13","doi-asserted-by":"publisher","unstructured":"Ba Y, Shi Y, Jiang W, Feng J, Cheng Y, Xiao L, Zhang Q, Qiu W, Xu B, Xu R, Shen B, Luo Z, Xie X, Chang J, Wang M, Li Y, Shuang Y, Niu Z, Liu B, Zhang J, Zhang L, Yao H, Xie C, Huang H, Liao W, Chen G, Zhang X, An H, Deng Y, Gong P, Xiong J, Yao Q, An X, Chen C, Shi Y, Wang J, Wang X, Wang Z, Xing P, Yang S, Zhou C (2020) Current management of chemotherapy-induced neutropenia in adults: key points and new challenges: Committee of Neoplastic Supportive-Care (CONS), China Anti-Cancer Association Committee of Clinical Chemotherapy, China Anti-Cancer Association. Cancer Biol Med 17(4):896\u2013909. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2020.0069\u00a0","DOI":"10.20892\/j.issn.2095-3941.2020.0069"},{"issue":"9","key":"4948_CR14","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1159\/000488688","volume":"41","author":"D Kauffmann-Guerrero","year":"2018","unstructured":"Kauffmann-Guerrero D, Kahnert K, Syunyaeva Z, Tufman A, Huber RM (2018) Pretherapeutic inflammation predicts febrile neutropenia and reduced progression-free survival after first-line chemotherapy in SCLC. Oncol Res Treat 41(9):506\u2013512","journal-title":"Oncol Res Treat"},{"key":"4948_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00692","volume":"10","author":"AT Xiao","year":"2020","unstructured":"Xiao AT, Tong YX, Xu XS, Zhou Y, Zhang S (2020) Preoperative nutritional status contributes to the development of neutropenia event in patients with gastric cancer receiving CAPEOX adjuvant chemotherapy. Front Oncol 10:692. https:\/\/doi.org\/10.3389\/fonc.2020.00692","journal-title":"Front Oncol"},{"issue":"4","key":"4948_CR16","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1111\/cas.12622","volume":"106","author":"M Shinoda","year":"2015","unstructured":"Shinoda M, Ando N, Kato K, Ishikura S, Kato H, Tsubosa Y, Minashi K, Okabe H, Kimura Y, Kawano T, Kosugi S, Toh Y, Nakamura K, Fukuda H, Japan Clinical Oncology Group (2015) Randomized study of low-dose versus standard-dose chemoradiotherapy for unresectable esophageal squamous cell carcinoma (JCOG0303). Cancer Sci 106(4):407\u2013412. https:\/\/doi.org\/10.1111\/cas.12622","journal-title":"Cancer Sci"},{"issue":"2","key":"4948_CR17","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1007\/s00520-023-07609-6","volume":"31","author":"K Nara","year":"2023","unstructured":"Nara K, Yamamoto T, Sato Y, Yagi K, Kawasaki K, Toriumi T, Takada T, Seto Y, Suzuki H (2023) Low pretherapy skeletal muscle mass index is associated with an increased risk of febrile neutropenia in patients with esophageal cancer receiving docetaxel + cisplatin + 5-fluorouracil (DCF) therapy. Support Care Cancer 31(2):150. https:\/\/doi.org\/10.1007\/s00520-023-07609-6","journal-title":"Support Care Cancer"},{"key":"4948_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.744129","volume":"12","author":"LA Potempa","year":"2021","unstructured":"Potempa LA, Rajab IM, Olson ME, Hart PC (2021) C-reactive protein and cancer: interpreting the differential bioactivities of its pentameric and monomeric, modified isoforms. Front Immunol 12:744129. https:\/\/doi.org\/10.3389\/fimmu.2021.744129","journal-title":"Front Immunol"},{"issue":"24","key":"4948_CR19","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.2217\/bmm-2023-0708","volume":"17","author":"SB Ali","year":"2023","unstructured":"Ali SB, Cecchin A, Lucchesi C, Putty T, Edwards S, Petrou T, Coates P, Ferrante A, Pucar PA, King J, Banovic T (2023) Can C-reactive protein be used as a surrogate marker of IL-6 in a broad array of clinical entities? Biomark Med 17(24):1001\u20131010. https:\/\/doi.org\/10.2217\/bmm-2023-0708","journal-title":"Biomark Med"},{"key":"4948_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1425168","volume":"15","author":"HH Zhou","year":"2024","unstructured":"Zhou HH, Tang YL, Xu TH, Cheng B (2024) C-reactive protein: structure, function, regulation, and role in clinical diseases. Front Immunol 15:1425168. https:\/\/doi.org\/10.3389\/fimmu.2024.1425168","journal-title":"Front Immunol"},{"issue":"10","key":"4948_CR21","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1007\/s00520-015-2650-8","volume":"23","author":"CW Wu","year":"2015","unstructured":"Wu CW, Wu JY, Chen CK, Huang SL, Hsu SC, Lee MT, Chang SS, Lee CC (2015) Does procalcitonin, C-reactive protein, or interleukin-6 test have a role in the diagnosis of severe infection in patients with febrile neutropenia? A systematic review and meta-analysis. Support Care Cancer 23(10):2863\u20132872. https:\/\/doi.org\/10.1007\/s00520-015-2650-8","journal-title":"Support Care Cancer"},{"key":"4948_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.762470","volume":"11","author":"Y Wang","year":"2021","unstructured":"Wang Y, Wang K, Ni J, Zhang H, Yin L, Zhang Y, Shi H, Zhang T, Zhou N, Mao W, Peng B (2021) Combination of C-reactive protein and neutrophil-to-lymphocyte ratio as a novel prognostic index in patients with bladder cancer after radical cystectomy. Front Oncol 11:762470. https:\/\/doi.org\/10.3389\/fonc.2021.762470","journal-title":"Front Oncol"},{"key":"4948_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.827788","volume":"13","author":"CL Han","year":"2022","unstructured":"Han CL, Meng GX, Ding ZN, Dong ZR, Chen ZQ, Hong JG, Yan LJ, Liu H, Tian BW, Yang LS, Xue JS, Li T (2022) The predictive potential of the baseline C-reactive protein levels for the efficiency of immune checkpoint inhibitors in cancer patients: a systematic review and meta-analysis. Front Immunol 13:827788. https:\/\/doi.org\/10.3389\/fimmu.2022.827788","journal-title":"Front Immunol"},{"issue":"1","key":"4948_CR24","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1002\/kjm2.12129","volume":"36","author":"Y Wang","year":"2020","unstructured":"Wang Y, Hu X, Huang Y, Xu WY, Wu YM, Li PF, Che GW (2020) Prognostic value of the C-reactive protein to albumin ratio in esophageal cancer: a systematic review and meta-analysis. Kaohsiung J Med Sci 36(1):54\u201361. https:\/\/doi.org\/10.1002\/kjm2.12129","journal-title":"Kaohsiung J Med Sci"},{"issue":"4","key":"4948_CR25","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3109\/10408363.2011.599831","volume":"48","author":"KH Allin","year":"2011","unstructured":"Allin KH, Nordestgaard BG (2011) Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer. Crit Rev Clin Lab Sci 48(4):155\u2013170. https:\/\/doi.org\/10.3109\/10408363.2011.599831","journal-title":"Crit Rev Clin Lab Sci"},{"issue":"12","key":"4948_CR26","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1172\/JCI18921","volume":"111","author":"MB Pepys","year":"2003","unstructured":"Pepys MB, Hirschfield GM (2003) C-reactive protein: a critical update. J Clin Invest 111(12):1805\u20131812. https:\/\/doi.org\/10.1172\/JCI18921","journal-title":"J Clin Invest"},{"issue":"Suppl 1","key":"4948_CR27","doi-asserted-by":"publisher","first-page":"s3","DOI":"10.1136\/thorax-2022-219699","volume":"78","author":"AJ Simpson","year":"2023","unstructured":"Simpson AJ, Allen JL, Chatwin M, Crawford H, Elverson J, Ewan V, Forton J, McMullan R, Plevris J, Renton K, Tedd H, Thomas R, Legg J (2023) BTS clinical statement on aspiration pneumonia. Thorax 78(Suppl 1):s3\u2013s21. https:\/\/doi.org\/10.1136\/thorax-2022-219699","journal-title":"Thorax"},{"issue":"4","key":"4948_CR28","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1097\/NCC.0000000000001205","volume":"47","author":"MY Liu","year":"2024","unstructured":"Liu MY, Wang CH, Lee SH, Chang WC, Wu CE, Liu HE (2024) Effectiveness of a protocol intervention for aspiration pneumonia prevention in patients with esophageal cancer during concurrent chemoradiotherapy: a randomized control trial. Cancer Nurs 47(4):327\u2013335. https:\/\/doi.org\/10.1097\/NCC.0000000000001205","journal-title":"Cancer Nurs"},{"issue":"2","key":"4948_CR29","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/s41423-020-00608-1","volume":"18","author":"J Florentin","year":"2021","unstructured":"Florentin J, Zhao J, Tai YY, Vasamsetti SB, O\u2019Neil SP, Kumar R, Arunkumar A, Watson A, Sembrat J, Bullock GC, Sanders L, Kassa B, Rojas M, Graham BB, Chan SY, Dutta P (2021) Interleukin-6 mediates neutrophil mobilization from bone marrow in pulmonary hypertension. Cell Mol Immunol 18(2):374\u2013384. https:\/\/doi.org\/10.1038\/s41423-020-00608-1","journal-title":"Cell Mol Immunol"},{"issue":"5","key":"4948_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0019957","volume":"6","author":"DW Cain","year":"2011","unstructured":"Cain DW, Snowden PB, Sempowski GD, Kelsoe G (2011) Inflammation triggers emergency granulopoiesis through a density-dependent feedback mechanism. PLoS ONE 6(5):e19957. https:\/\/doi.org\/10.1371\/journal.pone.0019957","journal-title":"PLoS ONE"},{"issue":"7","key":"4948_CR31","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20201541","volume":"218","author":"F Caiado","year":"2021","unstructured":"Caiado F, Pietras EM, Manz MG (2021) Inflammation as a regulator of hematopoietic stem cell function in disease, aging, and clonal selection. J Exp Med 218(7):e20201541. https:\/\/doi.org\/10.1084\/jem.20201541","journal-title":"J Exp Med"},{"issue":"8","key":"4948_CR32","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/j.stem.2022.06.012","volume":"29","author":"R Bogeska","year":"2022","unstructured":"Bogeska R, Mikecin AM, Kaschutnig P, Fawaz M, B\u00fcchler-Sch\u00e4ff M, Le D, Ganuza M, Vollmer A, Paffenholz SV, Asada N, Rodriguez-Correa E, Frauhammer F, Buettner F, Ball M, Knoch J, St\u00e4ble S, Walter D, Petri A, Carre\u00f1o-Gonzalez MJ, Wagner V, Brors B, Haas S, Lipka DB, Essers MAG, Weru V, Holland-Letz T, Mallm JP, Rippe K, Kr\u00e4mer S, Schlesner M, McKinney Freeman S, Florian MC, King KY, Frenette PS, Rieger MA, Milsom MD (2022) Inflammatory exposure drives long-lived impairment of hematopoietic stem cell self-renewal activity and accelerated aging. Cell Stem Cell 29(8):1273-1284.e8. https:\/\/doi.org\/10.1016\/j.stem.2022.06.012","journal-title":"Cell Stem Cell"},{"issue":"3","key":"4948_CR33","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.3390\/ijms23031125","volume":"23","author":"NP Ho","year":"2022","unstructured":"Ho NP, Takizawa H (2022) Inflammation regulates haematopoietic stem cells and their niche. Int J Mol Sci 23(3):1125. https:\/\/doi.org\/10.3390\/ijms23031125","journal-title":"Int J Mol Sci"},{"issue":"15","key":"4948_CR34","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1016\/j.ejca.2006.05.002","volume":"42","author":"MS Aapro","year":"2006","unstructured":"Aapro MS, Cameron DA, Pettengell R, Bohlius J, Crawford J, Ellis M, Kearney N, Lyman GH, Tjan-Heijnen VC, Walewski J, Weber DC, Zielinski C, European Organisation for Research and Treatment of Cancer (EORTC) Granulocyte Colony-Stimulating Factor (G-CSF) Guidelines Working Party (2006) EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 42(15):2433\u20132453. https:\/\/doi.org\/10.1016\/j.ejca.2006.05.002","journal-title":"Eur J Cancer"},{"issue":"1","key":"4948_CR35","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.lungcan.2011.01.020","volume":"74","author":"H Sheikh","year":"2011","unstructured":"Sheikh H, Colaco R, Lorigan P, Blackhall F, Califano R, Ashcroft L, Taylor P, Thatcher N, Faivre-Finn C (2011) Use of G-CSF during concurrent chemotherapy and thoracic radiotherapy in patients with limited-stage small-cell lung cancer safety data from a phase II trial. Lung Cancer 74(1):75\u201379. https:\/\/doi.org\/10.1016\/j.lungcan.2011.01.020","journal-title":"Lung Cancer"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04948-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-026-04948-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04948-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T07:42:59Z","timestamp":1789630979000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-026-04948-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4948"],"URL":"https:\/\/doi.org\/10.1007\/s00280-026-04948-z","relation":{},"ISSN":["1432-0843"],"issn-type":[{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,17]]},"assertion":[{"value":"2 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study involving human participants was conducted in accordance with the ethical standards of the institutional and national research committee, and adhered to the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The clinical study protocol was approved by the Ethics Committee of Oita University Faculty of Medicine (approval number: 1901). Because the study used existing clinical data and posed minimal risk, the requirement for individual informed consent was waived.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"105"}}